AC Immune (ACIU) Interest Coverage Ratio: History & Chart

AC Immune S.A.(ACIU)

Biotechnology · Lausanne, VD

$2.55-0.16 (-5.90%)

Delayed quote: Oct 6, 2026, 1:04 PM EDT

About AC Immune S.A.

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

Lausanne, VD

106 employees

www.acimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martin Zügel

View full financials

ACIU Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

-360.54x

INTEREST COVERAGE RATIO AVG TTM

-235.34x

INTEREST COVERAGE RATIO AVG 3Y

-353.06x

INTEREST COVERAGE RATIO AVG 5Y

-274.15x

INTEREST COVERAGE RATIO AVG 10Y

-244.13x

INTEREST COVERAGE RATIO AVG 15Y

N/A

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-53.20%

CURRENT VS 3Y AVG

-2.12%

CURRENT VS 5Y AVG

-31.51%

CURRENT VS 10Y AVG

-47.69%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-5.79x

median of 488 covered companies

CURRENT VS SECTOR MEDIAN

-6126.94%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
AC Immune S.A. (ACIU)	$259.52M	-360.54x	-235.34x	-353.06x	-274.15x
X4 Pharmaceuticals, Inc. (XFOR)vs ›	$259.46M	-9.79x	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$261.24M	-1805.60x	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$258.09M	N/A	130.06x	93.86x	75.34x
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$262.65M	-530.37x	N/A	N/A	N/A
Inhibikase Therapeutics, Inc. (IKT)vs ›	$264.73M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$265.41M	N/A	N/A	N/A	N/A
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$265.50M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$267.03M	N/A	N/A	N/A	N/A
Sol-Gel Technologies Ltd. (SLGL)vs ›	$251.29M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

AC Immune S.A. (ACIU)

$259.52M

-360.54x

-235.34x

-353.06x

-274.15x

X4 Pharmaceuticals, Inc. (XFOR)vs ›

$259.46M

-9.79x

N/A

Palisade Bio, Inc. (PALI)vs ›

$261.24M

-1805.60x

N/A

Anika Therapeutics, Inc. (ANIK)vs ›

$258.09M

N/A

130.06x

93.86x

75.34x

Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›

$262.65M

-530.37x

N/A

Inhibikase Therapeutics, Inc. (IKT)vs ›

$264.73M

N/A

OraSure Technologies, Inc. (OSUR)vs ›

$265.41M

N/A

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$265.50M

N/A

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$267.03M

N/A

Sol-Gel Technologies Ltd. (SLGL)vs ›

$251.29M

N/A

Interest Coverage Ratio FAQ

What is the interest coverage ratio for AC Immune S.A. (ACIU)?

The interest coverage ratio for ACIU stock is -360.54x.

Is AC Immune S.A.'s interest coverage ratio high or low?

The interest coverage ratio of -360.54x is 32% below its 5-year average of -274.15x, around the middle of its 5-year range (-631.33x–220.27x).

What is the TTM average interest coverage ratio for AC Immune S.A. (ACIU)?

The TTM average interest coverage ratio for ACIU stock is -235.34x.

What is the 3Y average interest coverage ratio for AC Immune S.A. (ACIU)?

The 3Y average interest coverage ratio for ACIU stock is -353.06x.

What is the 5Y average interest coverage ratio for AC Immune S.A. (ACIU)?

The 5Y average interest coverage ratio for ACIU stock is -274.15x.

What is the 10Y average interest coverage ratio for AC Immune S.A. (ACIU)?

The 10Y average interest coverage ratio for ACIU stock is -244.13x.

DATE	INTEREST COVERAGE RATIO
2026-06-30	19.56x
2026-03-31	-227.51x
2025-12-31	-345.63x
2025-06-30	-387.76x
2025-03-31	-358.70x
2024-12-31	-620.60x
2024-09-30	220.27x
2024-06-30	-616.50x
2024-03-31	-557.44x
2023-12-31	-136.19x
2023-09-30	-594.85x
2023-06-30	-631.33x
2023-03-31	-181.14x
2022-09-30	-174.84x
2022-06-30	-157.61x
2022-03-31	-122.27x
2021-12-31	-131.72x
2021-09-30	-112.06x
2021-06-30	-92.52x
2021-03-31	-663.50x
2020-12-31	-549.80x
2020-09-30	-408.80x
2020-06-30	280.13x
2020-03-31	-128.11x
2019-12-31	-77.63x
2019-09-30	206.10x
2019-06-30	-29.39x
2019-03-31	54.72x
2018-12-31	-62.19x
2018-09-30	-392.61x
2018-06-30	-518.37x
2018-03-31	-943.50x
2017-12-31	52.26x
2017-09-30	-876.36x
2017-06-30	-109.75x
2017-03-31	-4.79x
2016-09-30	-7.61x
2016-06-30	111.31x
2016-03-31	-14.76x
2015-12-31	-300.29x
2015-09-30	364.68x
2015-03-31	-1637.50x

DATE

INTEREST COVERAGE RATIO

2026-06-30

19.56x

2026-03-31

-227.51x

2025-12-31

-345.63x

2025-06-30

-387.76x

2025-03-31

-358.70x

2024-12-31

-620.60x

2024-09-30

220.27x

2024-06-30

-616.50x

2024-03-31

-557.44x

2023-12-31

-136.19x

2023-09-30

-594.85x

2023-06-30

-631.33x

2023-03-31

-181.14x

2022-09-30

-174.84x

2022-06-30

-157.61x

2022-03-31

-122.27x

2021-12-31

-131.72x

2021-09-30

-112.06x

2021-06-30

-92.52x

2021-03-31

-663.50x

2020-12-31

-549.80x

2020-09-30

-408.80x

2020-06-30

280.13x

2020-03-31

-128.11x

2019-12-31

-77.63x

2019-09-30

206.10x

2019-06-30

-29.39x

2019-03-31

54.72x

2018-12-31

-62.19x

2018-09-30

-392.61x

2018-06-30

-518.37x

2018-03-31

-943.50x

2017-12-31

52.26x

2017-09-30

-876.36x

2017-06-30

-109.75x

2017-03-31

-4.79x

2016-09-30

-7.61x

2016-06-30

111.31x

2016-03-31

-14.76x

2015-12-31

-300.29x

2015-09-30

364.68x

2015-03-31

-1637.50x

Interest Coverage Ratio: -360.54x

ACIU Interest Coverage Ratio

ACIU Average Interest Coverage Ratio Chart

ACIU Current vs Average Interest Coverage Ratio Chart

ACIU Interest Coverage Ratio Metrics

ACIU Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

ACIU Interest Coverage Ratio History

Related Metrics